

21 August 2025

Myeloma Treatment

I am writing to you under the Freedom of Information Act 2000 to request the following information:

1. Is your NHS Trust currently treating myeloma patients?

Yes

2. Please list the hospitals in your NHS Trust that are currently treating myeloma patients.

Belfast City Hospital

3. Please list how many myeloma patients are being treated by your NHS Trust. Please break this down by hospital.

During the 2024 calendar year (1st January 2024 to 31st December 2024), there were 110 admissions¹ to Belfast Health and Social Care Trust hospitals with a Primary Diagnosis of Myeloma.

¹ Figures provided relate to the number of admissions to hospital rather than number of patients. A patient could be admitted more than once with the same primary diagnosis and, therefore, would be counted for each admission.

Please note: Only patients admitted to hospital with a primary diagnosis of myeloma have been provided in this response. Diagnosis information for patients treated within the Outpatient, Diagnostic or Radiotherapy setting is not captured electronically and, as such, patients treated only in these settings have not been included in the figure provided above.

Please see below patients with a new diagnosis of Myeloma and treated in Belfast January to July 2025.

Month	Number Treated
January	<5
February	<5
March	<5
May	<5
June	9
July (provisional)	<5
Grand Total	23

Please note: July figures will be smaller due a tracking backlog.

21 August 2025

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

4. **Is your NHS Trust currently treating myeloma patients with elranatamab or teclistamab? Please break this down by hospital.**

Yes, Belfast City Hospital

5. **Please list how many people have been given a) elranatamab or b) teclistamab since approval by the National Institute of Health and Care Excellence in 2024 (TA1023 and TA1015). If possible, please break this down by hospital.**

Belfast Trust does not hold this information centrally, as electronic prescribing is not in place for Haematology. To retrieve the information would require a manual trawl of individual patient records, which would take more than 18 hours.

Belfast Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

6. **Do you have a service level agreement or referral system in place with any other NHS Trust to deliver a) elranatamab or b) teclistamab to patients? If the answer to question this question is yes, which NHS Trust do you have an agreement in place with?**

No